Survey of Prostate Cancer in Accra, Ghana

Sponsor
National Cancer Institute (NCI) (NIH)
Overall Status
Completed
CT.gov ID
NCT00339534
Collaborator
National Institute on Minority Health and Health Disparities (NIMHD) (NIH)
1,758
1
214.6
8.2

Study Details

Study Description

Brief Summary

This study, conducted at Korle-Bu Hospital in Accra, Ghana, will help elucidate the roles of lifestyle and genetic factors in prostate cancer risk. There is a strong variation in risk of prostate cancer throughout the world. The rates of the disease among African Americans are some of the world s highest. In the United States, the incidence of prostate cancer is 70 percent higher in African Americans than in white Americans and the death rate in African Americans is almost double that of white Americans. The reasons for this excessive risk are unknown, but both genetic and lifestyle factors have been suggested.

Because Africans and African Americans share similar genetic ancestry but have vastly different lifestyles, a better understanding of the rates and risk factor profiles for prostate cancer among Africans will provide important clues to what causes the disease. This study will try to assess the incidence of prostate cancer in the West African nation of

Ghana. The study has two components:
  • Clinical survey The methods of diagnosis at Korle-Bu will be evaluated and the incidence of prostate cancer over a 5-year period will be estimated.

  • Screening and detection survey A survey of 1,000 men between 50 and 74 years of age will estimate the prevalence of both asymptomatic and undiagnosed symptomatic prostate cancer in the Accra population.

The clinical survey will use data from the cancer logbook and medical records at Korle-Bu Hospital and the Ghanaian National Census to derive an estimate of prostate cancer incidence within Accra. The estimate will be low, since it will be based only on men diagnosed or treated at Korle-Bu and will not include men with asymptomatic disease, men diagnosed elsewhere, or men without access to medical care. The screening and detection survey will assess the presence of asymptomatic and unrecognized symptomatic prostate cancer using PSA testing and digital rectal examination in a random sample of 1,000 men in the general population of Accra. This will provide a high estimate of disease prevalence. The two estimates will provide an approximation of the true incidence rate of the disease in Accra.

Comparison of these data with similar data from community surveys of African Americans will provide insight into reasons for the excess risk of prostate cancer in African Americans.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    OBJECTIVE: The key aim of this study is to assess the burden of prostate cancer in Ghana and to evaluate how the impact of prostate cancer among West Africans compares with that among African Americans, whose reported incidence rates are among the highest in the world. West Africans and African Americans share genetic ancestry but have very different lifestyles and environmental exposures. The study aim will be achieved by establishing lower and upper bounds on the true incidence of prostate cancer in the capital city of Accra. The secondary aim of the study is to establish epidemiological, biochemical, and genetic profiles of West Africans for comparisons with African Americans to provide etiologic clues for prostate cancer. DESIGN: The study will consist of two components: 1. a clinical survey, a. divided into a five-year retrospective, and b. a 3-year prospective phase, and 2. a population screening survey.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    1758 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Retrospective
    Official Title:
    Survey of Prostate Cancer in Accra, Ghana
    Actual Study Start Date :
    Jun 26, 2002
    Actual Primary Completion Date :
    May 15, 2020
    Actual Study Completion Date :
    May 15, 2020

    Arms and Interventions

    Arm Intervention/Treatment
    Cases

    Cases were recruited at Korle Bu Teaching Hospital in Accra, Ghana, between 2008 and 2012.

    Controls

    Controls were selected in a population-based component using a probability sample designed with the 2000 Ghana Population and Housing Census data between 2004 and 2006.

    Outcome Measures

    Primary Outcome Measures

    1. Prostate cancer [At recruitment: case-control study]

      Prostate cancer (case-control observational/epidemiologic study)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 125 Years
    Sexes Eligible for Study:
    Male
    Accepts Healthy Volunteers:
    No
    • INCLUSION CRITERIA:

    The 1,000 Accra residents selected for screening will include 300 men 50-59, 400 men 60-69, and 300 men 70-74 years of age.

    EXCLUSION CRITERIA:

    Men who do not meet the age requirements will be excluded from the study.

    In addition, men who have a history of prostate cancer for which they have received treatment will also be excluded (men with untreated prostate cancer will be included).

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Ghana Medical-Korle Bu Teaching Hospital Accra Ghana

    Sponsors and Collaborators

    • National Cancer Institute (NCI)
    • National Institute on Minority Health and Health Disparities (NIMHD)

    Investigators

    • Principal Investigator: Michael B Cook, M.D., National Cancer Institute (NCI)

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    National Cancer Institute (NCI)
    ClinicalTrials.gov Identifier:
    NCT00339534
    Other Study ID Numbers:
    • 999902240
    • 02-C-N240
    First Posted:
    Jun 21, 2006
    Last Update Posted:
    May 20, 2020
    Last Verified:
    May 1, 2020
    Keywords provided by National Cancer Institute (NCI)
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 20, 2020